PErsonalized TReatment for Endometrial Carcinoma
ConditionEndometrial Adenocarcinoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-100
SponsorUniversity of Helsinki
About this trial
The goal of this clinical trial is to compare the efficacy of adjuvant therapies in women with stage I-II molecular integrated high-intermediate or high-risk endometrial carcinoma. Specifically, the invesigators want to compare:
* Chemotherapy vs. chemoradiotherapy in p53 abn subtype and nonendometrioid carcinomas. * Vaginal brachytherapy vs. whole pelvic radiotherapy in the MMR-D molecular subgroup. * Vaginal brachytherapy vs. whole pelvic radiotherapy in the NSMP molecular subgroup.
Eligibility criteria
Qualifiers
Age 18 to 100 years
WHO performance status 0 to 2
Stage I-II molecular integrated high-intermediate or high-risk endometrial carcinoma
Disqualifiers
Age <18 years or >100 years
WHO performance status >2
Uterine sarcoma
A history of malignancy within 5 years
Trial design
Treatments tested in this trial
- Comparison of chemotherapy vs. chemoradiotherapy
- Comparison of VBT vs. WPRT
Treatment groups
300 Participants
are divided into 3 treatment groupsSponsors and collaborators
University of Helsinki
Lead sponsor
Turku University Hospital
Collaborator
Tampere University Hospital
Collaborator
Kuopio University Hospital
Collaborator
Oulu University Hospital
Collaborator
Kymenlaakso Central Hospital Kotka Finland
Collaborator
Päijänne Tavastia Central Hospital
Collaborator
South Carelia Central Hospital
Collaborator
Source ClinicalTrials.gov